Aeglea BioTherapeutics : Costs Associated with Exit/Disposal

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to... | April 12, 2023

Related Keywords

Texas , United States , Michaelc Hanley , Kelly Boothe , Cortney Caudill , Linda Neuman , Aeglea Biotherapeutics , Jeffrey Goldberg , Exchange Commission , European Medicines Agency , Wedbush Securities Inc , Investor Relations Corporate Communications , Aeglea Biotherapeutics Inc , Nasdaq , Company Annual Report On Form , Ongoing Phase , Classical Homocystinuria , Begins Process , Explore Strategic , Dose Dependent Reduction , Total Homocysteine , Additional Dose Exploration , Longer Treatment Duration May , Percent Change , Baseline After , Pegtarviliase Treatment , Post Dose , Wedbush Securities , Middle East , Immedica Pharma , Marketing Authorization Application , Drug Designation , Pediatric Disease , Fast Track , European Medicines , Securities Litigation Reform Act , Annual Report , United States Securities , Investor Relations , Corporate Communications , Nc Stock Exchange , News , Information , Press Release , Eglea , Iotherapeutics , Nnounces , Interim , Results , Rom , Ngoing , Hase , Linical , Trial , F , Egtarviliase , Or , The , Treatment , Classical , Omocystinuria , End , Egins , Rocess Agle Us00773j1034 ,